These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9449120)

  • 1. Dendritic cells pick up the pace in trials.
    Veggeberg S
    Mol Med Today; 1997 Dec; 3(12):518-9. PubMed ID: 9449120
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunology and immunotherapy approaches for prostate cancer.
    Elkord E
    Prostate Cancer Prostatic Dis; 2007; 10(3):224-36. PubMed ID: 17420764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunotherapy of prostate and bladder cancer.
    Totterman TH; Loskog A; Essand M
    BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor immunotherapy: inching toward the finish line.
    Curiel TJ; Curiel DT
    J Clin Invest; 2002 Feb; 109(3):311-2. PubMed ID: 11827989
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunotherapy of prostate cancer.
    Doehn C
    Eur Urol; 2008 Apr; 53(4):681-3; discussion 684-5. PubMed ID: 18248878
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.
    Burch PA; Breen JK; Buckner JC; Gastineau DA; Kaur JA; Laus RL; Padley DJ; Peshwa MV; Pitot HC; Richardson RL; Smits BJ; Sopapan P; Strang G; Valone FH; Vuk-Pavlović S
    Clin Cancer Res; 2000 Jun; 6(6):2175-82. PubMed ID: 10873066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changes of dendritic cells in prostate cancer and dendritic cell-based immunotherapy].
    Qi SY; Wang M; Xu Y
    Zhonghua Nan Ke Xue; 2007 May; 13(5):453-6. PubMed ID: 17569266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens].
    Prikler L; Scandella E; Men Y; Engeler DS; Diener PA; Gillessen S; Ludewig B; Schmid HP
    Aktuelle Urol; 2004 Aug; 35(4):326-30. PubMed ID: 15459874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation.
    Waeckerle-Men Y; Allmen EU; von Moos R; Classon BJ; Scandella E; Schmid HP; Ludewig B; Groettrup M; Gillessen S
    Prostate; 2005 Sep; 64(4):323-31. PubMed ID: 15754347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Numerical and functional assessment of blood dendritic cells in prostate cancer patients.
    Wilkinson R; Kassianos AJ; Swindle P; Hart DN; Radford KJ
    Prostate; 2006 Feb; 66(2):180-92. PubMed ID: 16173035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic and functional differences of dendritic cells generated under different in vitro conditions.
    McArdle SE; Ali SA; Li G; Mian S; Rees RC
    Methods Mol Med; 2003; 81():359-75. PubMed ID: 12725131
    [No Abstract]   [Full Text] [Related]  

  • 14. [State of the art about new therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells and recombinant virus].
    Eymard JC; Gervais A; Jarcau R; Bernard J
    Bull Cancer; 2007 Jul; 94(7 Suppl):F69-76. PubMed ID: 17845996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell vaccines for the treatment of prostate cancer.
    Lehrfeld TJ; Lee DI
    Urol Oncol; 2008; 26(6):576-80. PubMed ID: 18996314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer.
    Trudel S; Trachtenberg J; Toi A; Sweet J; Li ZH; Jewett M; Tshilias J; Zhuang LH; Hitt M; Wan Y; Gauldie J; Graham FL; Dancey J; Stewart AK
    Cancer Gene Ther; 2003 Oct; 10(10):755-63. PubMed ID: 14502228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
    Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
    Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical applications of dendritic cell vaccines.
    Morse MA; Lyerly HK
    Curr Opin Mol Ther; 2000 Feb; 2(1):20-8. PubMed ID: 11249649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DC therapy for prostate cancer.
    Swindle PW; Tepes S; Clements J
    Cytotherapy; 2004; 6(2):164-71. PubMed ID: 15203993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer.
    Cannon MJ; O'Brien TJ; Underwood LJ; Crew MD; Bondurant KL; Santin AD
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):97-105. PubMed ID: 12113075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.